Evidence map›Paper›PMID 34764257›Full record

ArticleNature communications2021

Deciphering cell lineage specification of human lung adenocarcinoma with single-cell RNA sequencing.

Zhoufeng Wang, Zhe Li, Kun Zhou, Chengdi Wang, Lili Jiang, Li Zhang, Ying Yang, Wenxin Luo, Wenliang Qiao, Gang Wang and 9 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers.

0numbers the graph read from it
0cells of the map it votes in
133citing papers in PubMed
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

133 citing papers in PubMed, 193 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

73 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Zhoufeng Wang *Department of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Zhe Li *Singlera Genomics Ltd, Shanghai, China.
Kun Zhou *Department of Thoracic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Chengdi Wang *Department of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Lili JiangDepartment of Pathology, West China Hospital of Sichuan University, Chengdu, China.
Li ZhangDepartment of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Ying YangDepartment of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Wenxin LuoDepartment of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Wenliang QiaoLung Cancer Center, West China Hospital Sichuan University, Chengdu, Sichuan, China.
Gang WangPrecision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yinyun NiDepartment of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Shuiping DaiCenter of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Tingting GuoDepartment of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Guiyi JiHealth Management Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Minjie XuSinglera Genomics Ltd, Shanghai, China.
Yiying LiuSinglera Genomics Ltd, Shanghai, China.
Zhixi SuSinglera Genomics Ltd, Shanghai, China.
Guowei CheDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China. cheguowei_hx@aliyun.com.ORCID http://orcid.org/0000-0002-5779-8274
Weimin LiDepartment of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China. weimi003@scu.edu.cn.ORCID http://orcid.org/0000-0003-0985-0311
Sichuan University · CNSinotech Genomics (China) · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung adenocarcinomas (LUAD) arise from precancerous lesions such as atypical adenomatous hyperplasia, which progress into adenocarcinoma in situ and minimally invasive adenocarcinoma, then finally into invasive adenocarcinoma. The cellular heterogeneity and molecular events underlying this stepwise progression remain unclear. In this study, we perform single-cell RNA sequencing of 268,471 cells collected from 25 patients in four histologic stages of LUAD and compare them to normal cell types. We detect a group of cells closely resembling alveolar type 2 cells (AT2) that emerged during atypical adenomatous hyperplasia and whose transcriptional profile began to diverge from that of AT2 cells as LUAD progressed, taking on feature characteristic of stem-like cells. We identify genes related to energy metabolism and ribosome synthesis that are upregulated in early stages of LUAD and may promote progression. MDK and TIMP1 could be potential biomarkers for understanding LUAD pathogenesis. Our work shed light on the underlying transcriptional signatures of distinct histologic stages of LUAD progression and our findings may facilitate early diagnosis.

Indexed as

Adenocarcinoma of LungCell LineageEnergy MetabolismHumansLung NeoplasmsMidkineRibosomesTissue Inhibitor of Metalloproteinase-1MDK protein, humanMidkineTIMP1 protein, humanTissue Inhibitor of Metalloproteinase-1

Identifiers

PMID34764257
PMCPMC8586023
OpenAlexW3197945601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.